Generic imatinib entered the US market on February 1, 2016, at 96 percent of the price of branded Gleevec. Sun
The Specialty Pharmacy Margin Everyone Protects Disappears the Day a Generic Launches Read Post »
On July 1, 2026, a federal judge in Denver blocked Colorado’s price cap on Enbrel. The board that set the
In 2015, a Delaware federal judge looked at prior art covering an antioxidant added to a rivastigmine skin patch and
The Forum You File In Changes Your Odds More Than the Merits Do Read Post »
The Short Answer Six months is the optimistic case. When Amgen launched the first Humira biosimilar on January 31, 2023,
On October 2, 2023, the Patent Trial and Appeal Board refused to institute Mylan’s inter partes review of two Novo
On October 16, 2018, adalimumab biosimilars went on sale across Germany, France and the rest of the European Union. On
Why a Drug Off-Patent in Europe Can Still Be Protected for Three More Years in the US Read Post »
DrugPatentWatch tracks generic entry dates for a living, and one pattern shows up over and over in support calls from
A drug that never reaches patients usually did not fail a safety test. In a systematic review of 115 published
Shelved, Not Failed: How AI Finds the Medicines Pharma Abandoned on Purpose Read Post »
Abilify Maintena lost its patent-based market exclusivity in the European Union and the United States in October 2024 [1][2]. In
Three Clocks, One Patent: The Extension Gap Between Australia, Canada, and the EU Read Post »
Sign in or create a free account to read this DrugPatentWatch article
